Document 0574
 DOCN  M9650574
 TI    Recombinant gp160 vaccination schedule and MHC HLA type as factors
       influencing cellular responses to HIV-1 envelope glycoprotein. NIAID
       AIDS Vaccine Clinical Trials Network.
 DT    9605
 AU    Gorse GJ; Patel GB; Newman FK; Mandava M; Belshe RB; Division of
       Infectious Diseases, St. Louis University Health; Sciences Center, MO
       63110-0250, USA.
 SO    Vaccine. 1995 Sep;13(13):1170-9. Unique Identifier : AIDSLINE
       MED/96118124
 AB    This study assessed (1) T-cell responses following vaccination of HIV-1
       negative volunteers with HIV-1LAI recombinant gp160 (rgp160) vaccine,
       and (2) effects of vaccine injection schedule and MHC HLA type on those
       responses. In one trial, volunteers received rgp160 in two accelerated
       schedules (Groups 1 and 2). In the other trial, volunteers received
       rgp160 vaccine at 0, 1, 6, and 12 months and some received vaccine at 18
       months (Groups 3 and 4). Peripheral blood mononuclear cells (PBMC) from
       vaccinees in Groups 3 and 4 were stimulated by more peptides
       representing envelope glycoprotein T-cell epitopes than Groups 1 and 2
       (p = 0.01). Transient anti-envelope glycoprotein CTL activity was more
       frequently detectable in Groups 1 and 2 (p = 0.03). MHC HLA-Cw7, DR1 and
       DQw1 alleles appeared to be associated with PBMC responses to envelope
       glycoprotein.
 DE    Amino Acid Sequence  Animal  AIDS Vaccines/*ADMINISTRATION & DOSAGE
       Cattle  Cell Division/IMMUNOLOGY  Cytotoxicity Tests, Immunologic  Gene
       Products, env/*IMMUNOLOGY  Histocompatibility Antigens/*IMMUNOLOGY
       HIV-1/*IMMUNOLOGY  Immunity, Cellular  Immunization Schedule
       Lymphocytes/CYTOLOGY  Male  Molecular Sequence Data  Peptides/IMMUNOLOGY
       Protein Precursors/*IMMUNOLOGY  Support, U.S. Gov't, P.H.S.  Vaccines,
       Synthetic/*ADMINISTRATION & DOSAGE  CLINICAL TRIAL  CLINICAL TRIAL,
       PHASE I  JOURNAL ARTICLE  RANDOMIZED CONTROLLED TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).